Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma

Terence CW Poon, Clarissa HS Chiu, Paul BS Lai, Tony SK Mok, Benny Zee, Anthony TC Chan, Joseph JY Sung, Philip J Johnson

METHODS: Preoperative sera, paired tumorous and non-tumorous tissues were collected from 19 consecutive patients who had undergone surgical resection of HCC. ST6Gal I activities in the tissues were measured by an in vitro microsomal enzyme activity assay. The percentages of tumor-specific msAFP in the sera were also estimated by an isoelectric focusing-immunoblotting assay.

RESULTS: The tumor ST6Gal I activity was negatively correlated with serum msAFP percentage (r = -0.53, P = 0.019). Both decreased tumor ST6Gal I activity and increased serum msAFP percentage were associated with shorter overall survival. Multivariate analysis using the Cox regression model showed that the preoperative serum msAFP percentage (P = 0.022) and tumor cell differentiation status (P = 0.048) were independent prognostic indicators for patient overall survival.

CONCLUSION: Our results indicate that the presence of msAFP in blood circulation is associated with a decreased activity of ST6Gal I activity in HCC. Both tissue ST6Gal I and serum msAFP are potential prognostic markers for patients with operable HCC.

Key words: Alpha-fetoprotein; Beta-galactoside alpha-2,6-sialyltransferase; Hepatocellular carcinoma; Patient survival; Cell differentiation

INTRODUCTION

Beta-galactoside alpha-2,6-sialyltransferase (ST6Gal I) is the key enzyme for the production of alpha-2,6-linked sialoglycoconjugates. Both ST6Gal I and alpha-2,6-linked sialoglycoconjugates have been suggested to play important roles in oncogenic transformation and metastasis. Upregulated expression of ST6Gal I has been shown in colorectal cancer, breast cancer, cervical cancer, and choriocarcinoma. However, elevated alpha-2,6 sialylation inhibited formation of glioma in vitro. Expression of ST6Gal I may have different effects in different cancer types.

Serum alpha-fetoprotein (AFP) is a conventional marker for the diagnosis of hepatocellular carcinoma. Eighty to ninety percent of patients with HCC will have levels above the reference range. A serum concentration >500 μg/L, in an area with high incidence of HCC,
and in the appropriate clinical setting, is usually considered diagnostic of HCC. However, modestly raised levels of AFP (10-500 μg/L) are also common in non-malignant chronic liver disease, so that the specificity of the AFP test for HCC tends to be low[10,13-15]. Recent studies have shown that monosialylated AFP (msAFP), which is a hyposialylated isofrm of alpha-fetoprotein (AFP), is specific to hepatocellular carcinoma (HCC)[16,17]. msAFP can be identified, measured quantitatively by isoelectrofocusing electrophoresis approach or by glycosylation immunosorbent assay[18], msAFP percentage (msAFP%) relative to total AFP can be used as a serum marker to differentiate HCC patients with non-diagnostic total AFP from patients with chronic liver diseases[19].

Sialylation of AFP is mediated by cellular ST6Gal I. We hypothesize that downregulation of ST6Gal I plays an important role in the HCC pathogenesis, and causes the presence of msAFP in blood circulation of HCC patients. In the present study, we examined the enzyme activity and mRNA expression of ST6Gal I in the paired tumorous and non-tumorous tissues from patients with HCC. The correlation among ST6Gal I activity, serum msAFP percentage and their clinical implications were investigated.

MATERIALS AND METHODS

Clinical materials

Between December 1999 and January 2001, 19 consecutive patients who had undergone surgical resection of HCC, which contained viable tumor cells as shown by histological examination, and with serum AFP levels higher than 20 ng/mL were recruited into this study. Informed consent was obtained for using the resected tissues and sera for research studies. The patients were followed up for 2 years or until death. Preoperative sera, paired tumorous and non-tumorous tissues were collected. Sera were stored at -20 °C until further analysis. The tissues were cut into small pieces, snap frozen with liquid nitrogen, and stored at -70 °C. The AFP levels in the serum samples were quantified with a commercial sandwich-type ELISA (DAKO, Glostrup, Denmark). This study was approved by the Joint CUHK-N TEC Clinical Research Ethics Committee.

Preparation of tissue microsomal fraction

The tissues were homogenized on ice in 1 mL of sodium phosphate buffer (PBS, 10 mmol/L NaPO₄, 150 mmol/L NaCl, pH 7.4), containing 0.8 mmol/L protease inhibitor (Pefabloc SC PLUS, Boehringer Mannheim, Roche Diagnostics, Germany), with a Polytron-Aggregate (Kinetica, Switzerland) using a 11-mm cutting probe at a speed setting of 5 for 15 s. After centrifugation at 4 °C for 10 min at 10 000 r/min, the supernatant fraction was saved and centrifuged again at 13 000 g for 30 min at 4 °C. The microsomal pellet obtained after centrifugation was then resuspended in Tris-HCl buffer (15 mmol/L Tris-HCl, pH 6.0) and stored at -70 °C until analyzed. The protein content was measured by the Bradford Coomassie Dye-Binding Protein Assay.

ST6Gal I activity assay

The assay was similar to the method described by Pousset et al[19] and Halliday et al[20]. It was based on the specific binding property of Sambucus nigra agglutinin (SNA, Calibiochem, San Diego, USA) that preferentially binds sialic acid residues attached to terminal Galβ1,4GlcNAc units on N-glycan in alpha-2,6, but not 2,3 or 2,8 linkage.

Briefly, the microsomal preparation was used as a source of alpha-2,6-sialyltransferase, and the N-glycan on asialofetuin (ASF) (Sigma, St. Louis, USA) was used as a sialic acid acceptor. The ST6Gal I activity assay was carried out in a mixture containing 10 μg of tissue microsomal preparation, 125 μg ASF, 125 μmol/L CMP-sialic acid and 0.25 μCi CMP-[H]-sialic acid in reaction buffer (0.1% BSA, 0.1% Triton X-100, 45 mmol/L NaCl, 15 mmol/L Tris-HCl, pH 6.0) with a final volume of 20 μL. The mixture was added to 30 μL of SNA-sepharose (1 mg SNA covalently linked to 0.3 g of CNBr activated Sepharose 4B gel), mixed, and incubated at 37 °C overnight. After washing the gels four times with washing buffer (PBS containing 0.5% Tween 20), the molecules bound to the SNA-Sepharose were released by vortexing the gel in 300 μL of 1 mol/L H₂SO₄ for 30 s. Two hundred and eighty-five microliters of the supernatant was transferred to a vial, and 5 mL scintillant solution was added. The amount of radiolabeled AFP was then measured with a liquid scintillation counter. Commercial rat ST6Gal I (Sigma) was used as the calibration standard. One unit of the commercial rat ST6Gal I is defined as the amount that will transfer 1.0 μmol of sialic acid from CMP-sialic acid to asialomucin per minute at pH 6.5.

Semi-quantification of ST6Gal I mRNA by RT-PCR-ELISA

Ten to thirty milligrams of frozen tumorous or non-tumorous liver tissue was disrupted and homogenized using a mortar and pestle (Kontes, Vineland, NJ, USA). Total RNA was extracted from the tissue sample using the RNeasy Mini Kit (Qiagen, GmbH, Germany), and reverse transcribed into cDNA by using a 1st strand cDNA Synthesis Kit (AMV, Roche Diagnostics, Boehringer Mannheim, Germany) with the oligo(dT)₁₅ primer provided. The cDNA was then used as the template for PCR amplification with primers specific to ST6Gal I (forward: 5'-CCTGAAACATTCCAGCCT GCTCCITT-3' and reverse: 5'-GACGATGTGTTCCA ATCCCCGTGACCA-3') or β-actin gene (forward, 5' -CTTCTCAATGAGCTGGT-3' and reverse: 5'TCAT GAGGTATCGTCAG-3'). In the PCR for ST6Gal I, the cDNA, diluted in Tris-EDTA buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0), was mixed with 1×PCR buffer, 2 mmol/L DIG-labeled dNTP, 2.5 mmol/L MgCl₂, 1 μmol/L of each primer, 0.83 U Taq DNA polymerase, 0.022 μmol/L TaqStart Antibody, 0.8 U uracil glycosylase in a final volume of 20 μL. The mixture was incubated at room temperature for 10 min. Then an initial denaturation step of 2 min at 94 °C was done, followed by repeating
cycles of 1 min at 94 °C, 1 min at 63 °C for primer annealing, and 1 min at 72 °C for extension. A final extension run of 7 min at 72 °C was performed to ensure complete elongation of all amplicons. In the PCR for β-actin gene, 3.5 mmol/L of MgCl₂ was used instead of 2.5 mmol/L, and the primer annealing temperature in each PCR cycle was 60 °C instead of 63 °C. In the initial attempts, 40 cycles of PCR were performed. The specificity of the PCR amplification was checked by agarose gel electrophoresis to see if the sizes of the amplicons were the same as the expected values, 421 bp for ST6Gal I cDNA and 305 bp for β-actin gene. A commercially available cDNA preparation of human normal liver tissues, pooled from two male/female Caucasians, was used as positive control (Clontech Laboratories, Inc., CA, USA).

For the semi-quantitative assay, 25 cycles of PCR were performed in the presence of DIG-labeled dNTP. The concentrations of the DIG-labeled amplicons were measured with the PCR ELISA (DIG-detection) kit (Roche Diagnostics), according to the manufacturer's instruction. Briefly, the DIG-labeled amplicons were first denatured, and hybridized with 7.5 pmol biotinylated DNA probe specific for the ST6Gal I (biotin-5'-TGCATTGGGCACAATTGTAA-3') or β-actin gene (biotin-5'-GTCCAGACGGAGGATGGCAT-3'). The DNA-probe hybrids were then captured onto an avidin-coated microplate. After washing, the amount of the DNA-probe hybrids bound to the microplate was determined by incubating with anti-DIG-HRP conjugate at 37 °C for 30 min, followed by adding the BM Blue peroxidase substrate (Roche Diagnostics), according to the manufacturer's instruction. One hundred microliters of 1 mol/L H₂SO₄ was added to stop the colorimetric reaction. The optical density of the wells was determined at 450 nm with a densitometer (GS-700, Bio-Rad, CA, USA), and the percentage density of each band was expressed as a percentage of the total intensity of all AFP bands.

**RESULTS**

**Two HCC subgroups with increased and decreased tumor ST6Gal I activities**

The clinical features of the 19 patients with primary HCC are summarized in Table 1. The tumor ST6Gal I activity was compared to that of the paired non-tumorous tissue. Seven HCC patients fell into a group with decreased ST6Gal I activity in the tumorous tissue, whereas 12 HCC patients fell into a group with increased ST6Gal I activity in the tumorous tissue (Table 2). The tumor ST6Gal I activities in the decreased group were significantly lower than the values in the increased group (P = 0.005).

**Absence of correlation between ST6Gal I activity and mRNA level in HCC**

The specificity of the RT-PCR reaction was checked by subjecting the RT-PCR product to agarose gel electrophoresis. In all cases including the positive control (normal human liver cDNA), the RT-PCR product appeared as a single DNA band with the expected size of 421 bp for ST6Gal I, or 305 bp for β-actin. The electrophoresis results indicated that the RT-PCR amplifications were specific. Our data also confirmed that ST6Gal I gene was expressed in all the HCC tissues and the non-tumorous liver tissues (Figure 1). Two cases were omitted for the RT-PCR ELISA to measure ST6Gal I mRNA level owing to insufficient tissue materials. The measured ST6Gal I mRNA level of individual tissues was normalized by expressing the data as a ratio of β-actin mRNA level. In the non-tumorous tissues, the ST6Gal I mRNA level positively correlated with the ST6Gal I activity (r = 0.49, P = 0.039). In the tumorous tissues, no significant correlation was found between the enzyme activity (r = -0.093, P = 0.72).

**Correlation between tumor ST6Gal I enzyme activity and serum msAFP**

The percentages of tumor-specific msAFP (relative to total intensity of AFP isoforms) in the preoperative sera of the HCC patients were estimated, and the results of the patient groups with increased and decreased tumor ST6Gal I enzyme activity are shown in Table 2. Comparison of the
two groups shows that the percentage of msAFP in the patient group with decreased tumor enzyme activity was significantly higher than those in the group with increased activity \((P = 0.031)\), whereas the serum total AFP levels were not significantly different. Furthermore, the msAFP percentage was negatively correlated with the relative tumor ST6Gal I enzyme activity \((r = -0.53, P = 0.019)\).

**Associations with poorly differentiated HCC**

The relationships between ST6Gal I activity, msAFP percentage and various patient clinical parameters, including HBV status, tumor stage (ALTSG and AJCC), tumor size, differentiation status, vascular invasion, encapsulation, capsule invasion, metastasis and recurrent, were investigated. More cases with poorly differentiated tumor were found in the patient groups with decreased enzyme activity \((P = 0.045, Figure 2)\). Similar to tumor ST6Gal I activity, but in an opposite manner, more cases with poorly differentiated tumor were found in the patient group with higher (>20%) msAFP percentage \((P = 0.045, Figure 2)\).

**Associations with poor overall survival**

During the 2 years follow-up period, 8 out of the 19 patients died. The absolute/relative tumor ST6Gal I activity, serum msAFP percentage, serum AFP level and various patient clinical parameters were subjected to survival analyses. In univariate analyses using the Cox regression model, the preoperative serum msAFP percentage at a cut-off value of 20%, the log-rank test results showed that the patient group with increased activity and the tumor differentiation status \((P = 0.031)\) were shown to be predictors for patient overall survival. The log-rank test results showed that the patient group with decreased tumor ST6Gal I activity had an overall survival \((P = 0.0099, Figure 3A)\) shorter than the group with increased activity. When the cases were divided into two groups based on the preoperative serum msAFP percentage, the log-rank test results showed that higher preoperative serum msAFP percentage was associated with poorer patient overall survival \((P = 0.0031, Figure 3B)\). The log-rank test results also showed that patients with poorly differentiated tumor had poorer overall survival \((P = 0.0063)\). In a multivariate analysis using the Cox regression model, among all the

**Table 1 Clinical features of the studied subjects with operable HCC**

| Case | Sex | Age | HBs Ag positivity | Cirrhosis | Tumor stage | Tumor size (cm) | Tumor differentiation | Encapsulation | Capsule invasion | Vascular invasion | Preoperative serum AFP (ng/mL) |
|------|-----|-----|-------------------|----------|------------|-----------------|---------------------|---------------|-----------------|-----------------|-------------------------|
| 1    | F   | 51  | Yes               | Yes      | T2         | T2              | 2.4                 | Moderate       | Yes             | Yes             | No                      | 20                       |
| 2    | M   | 75  | Yes               | Yes      | T2         | T2              | 3.4                 | Moderate       | Yes             | Yes             | No                      | 25                       |
| 3    | M   | 52  | Yes               | No       | T3         | T2              | 10                  | Moderate       | Yes             | No              | No                      | 64                       |
| 4    | M   | 44  | Yes               | Yes      | T3         | T3              | 4                   | Doll           | Yes             | Yes             | Yes                     | 69                       |
| 5    | M   | 44  | No                | Yes      | T2         | T2              | 2.6                 | Poor           | Yes             | Yes             | No                      | 73                       |
| 6    | M   | 53  | Yes               | Yes      | T3         | T2              | 8.3                 | Poor           | Uncertain       | Uncertain       | No                      | 100                      |
| 7    | M   | 65  | No                | Yes      | T2         | T2              | 4.4                 | Moderate       | Yes             | No              | No                      | 150                      |
| 8    | F   | 41  | Yes               | Yes      | T3         | T2              | 7                   | Well           | Yes             | Yes             | No                      | 151                      |
| 9    | M   | 57  | No                | Yes      | T3         | T2              | 6                   | Poor           | Yes             | Yes             | Yes                     | 152                      |
| 10   | M   | 46  | Yes               | Yes      | T1         | T1              | 1.2                 | Moderate       | Yes             | Yes             | No                      | 365                      |
| 11   | M   | 60  | Yes               | Yes      | T2         | T2              | 2.2                 | Poor           | Yes             | Yes             | No                      | 618                      |
| 12   | M   | 67  | Yes               | Yes      | T2         | T2              | 2.5                 | Moderate       | Yes             | Yes             | No                      | 1 057                    |
| 13   | M   | 48  | Yes               | No       | T2         | T2              | 4                   | Moderate       | Yes             | No              | No                      | 1 427                    |
| 14   | M   | 43  | Yes               | No       | T2         | T2              | 2.5                 | Moderate       | Yes             | Yes             | No                      | 1 500                    |
| 15   | F   | 31  | Yes               | Yes      | T2         | T2              | 2                   | Moderate       | Yes             | Yes             | No                      | 2 726                    |
| 16   | M   | 40  | Yes               | No       | T2         | T2              | 1.6                 | Moderate       | No              | No              | No                      | 3 338                    |
| 17   | M   | 35  | Yes               | No       | T3         | T2              | 8                   | Poor           | Yes             | No              | No                      | 5 505                    |
| 18   | M   | 42  | Yes               | Yes      | T2         | T2              | 3.4                 | Poor           | Yes             | Yes             | Yes                     | 12 185                   |
| 19   | M   | 72  | Yes               | No       | T3         | T3              | 6.5                 | Poor           | Yes             | Yes             | No                      | 42 837                   |

**Table 2 The average values of relative ST6Gal I activity, the relative ST6Gal I mRNA level, serum msAFP percentage in the patients with decreased (group 1) and increased (group 2) tumor ST6Gal I activity compared to that of non-tumorous tissue**

| Group 1: decreased ST6Gal (n = 7) | Group 2: increased ST6Gal (n = 12) | p<sup>1</sup> |
|----------------------------------|------------------------------------|---------------|
| Tumor ST6Gal I activity (mU/mg of protein) | 0.57 (0.47, 0.37-0.59) | 1.76 (1.21, 0.94-1.93) | 0.005 |
| Relative tumor ST6Gal I activity (against non-tumor ST6Gal I activity) | 0.46 (0.42, 0.25-0.71)<sup>2</sup> | 2.04 (1.51, 1.35-1.88) | <0.001 |
| Tumor ST6Gal I mRNA level<sup>3</sup> | 1.78 (0.64, 0.24-1.7) | 1.51 (1.08, 0.68-2.6) | N.S<sup>4</sup> |
| Serum AFP level (ng/mL) | 7687 (680, 246-145045) | 739 (161, 724197) | N.S. |
| Serum msAFP percentage (%) | 35 (41, 23-45) | 18 (13, 11-17) | 0.031 |

<sup>1</sup>Mann–Whitney test; <sup>2</sup>mean (median, 25<sup>th</sup>-75<sup>th</sup> percentile); <sup>3</sup>group 1: n = 6, group 2: n = 11; <sup>4</sup>N.S., not significant.
et al.’s observation. Compared to non-tumorous tissue, the HCC patients could be divided into two groups with increased and decreased ST6Gal I activity in the tumorous tissue. By immunohistochemical staining, Cao et al. showed that expression levels of ST6Gal I were decreased in poorly differentiated HCC. This is also consistent to our observation that poorly differentiated HCCs had lower ST6Gal I activities.

The present study provided additional information about ST6Gal I in HCC. We showed that changes of ST6Gal I activity in HCC positively correlated with the presence of msAFP in blood circulation. As sialylation of AFP is mediated by ST6Gal I, probably the presence of hyposialylated AFP variants in blood circulation is caused by decreased ST6Gal I activity. Furthermore, our data suggests that tissue ST6Gal I and serum msAFP are potential prognostic markers for patients with operable HCC.

In the non-tumorous tissues, ST6Gal I mRNA level positively correlated with ST6Gal I activity. This result is consistent to the observation of Svensson et al.[25] when studying normal liver. This result therefore could be served as a positive control to confirm the validity of our measurements of tissue ST6Gal I activity and mRNA level. No significant correlation was found in the tumorous tissues. This suggests that ST6Gal I activity in HCC is regulated at post-transcriptional level.

The present study and the studies from Cao et al. and Dall'Olio et al.[8] strongly indicate that the functional roles of ST6Gal I in HCC are different from those in colorectal cancer and in breast cancer. An in vitro antisense DNA experiment has shown that upregulation of ST6Gal I plays an important role in the invasive potential of human colon carcinoma HT29 cells. Furthermore, high expression levels of ST6Gal I have been correlated with poor survival in colorectal cancer patients[25]. In breast cancers, high ST6Gal I expression was associated with histoprognostic grade III, and negatively correlated to progesterone receptor expression[26]. However, no ST6Gal I expression was found in malignant gliomas or in medulloblastomas[26].

It is worth noting that elevated alpha-2,6 sialylation...
inhibited formation of glioma in vivo\(^1\). All these findings indicate that expression of ST6Gal may have different effects in different cancer types.

In conclusion, HCC can be divided into two subtypes, one with decreased tumor ST6Gal I activity and one with increased tumor ST6Gal I activity. The ST6Gal I activity in HCC is not regulated at the transcription level. Downregulation of tumor ST6Gal I activity and an increase in msAFP percentage in preoperative serum are associated with poorly differentiated tumors and poor patient survival. Both ST6Gal I and msAFP percentage are potential prognostic markers for HCC. The presence of msAFP in the blood circulation probably reflects the downregulation of ST6Gal I activity in the HCC tissue.

REFERENCES

1. Collard JG, Schijven JP, Bikker A, La Riviere G, Bolscher JG, Roos E. Cell surface sialic acid and the invasive and metastatic potential of T-cell hybridomas. Cancer Res 1986; 46: 3521-3527
2. Le Marer N, Laude T, Svensson EC, Cazarius H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P. The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast (FRT3) cells. Glycobiology 1992; 2: 49-56
3. Zhu Y, Srivatana U, Ullah A, Gagheja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta 2001; 1536: 148-160
4. Dall'Olio F, Malagolini N, Serafini-Cessi F. Enhanced CMP-NeuAc:Gal beta1,4GlcNAc-R alpha 2,6-sialyltransferase activity of human colon cancer xenografts in athymic nude mice and of xenograft-derived cell lines. Int J Cancer 1992; 50: 325-330
5. Bresalier RS, Ho SB, Schoepfner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JV. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996; 110: 1354-1367
6. Recchi MA, Hebbel R, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res 1998; 58: 4066-4070
7. Wang PH, Li YF, Jiang CM, Lee YR, Chao HT, Tsai YC, Yuan CC. Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. Gynecol Oncol 2001; 83: 121-127
8. Fukushima K, Hara-Kuge S, Seko A, Ikehara Y, Yamashita K. Elevation of alpha2-6 sialyltransferase and alpha1--2 fucosyltransferase activities in human choriocarcinoma. Cancer Res 1998; 58: 4301-4306
9. Yamamoto H, Oviedo A, Sweeney C, Saito T, Moskal JR. Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo. Cancer Res 2001; 61: 6822-6829
10. Johnson PJ, Portmann B, Williams R. Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J 1978; 2: 661-663
11. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
12. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700-1707
13. Lok AS, Lai CL. Alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110-115
14. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6: 729-738
15. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notarisi S, Rada E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575
16. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Ho SK, Welby C, Stevenson D, Patel T, Paredk R, Townsend RR. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer 1999; 81: 1188-1195
17. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000; 83: 1330-1337
18. Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsai SH, Leung TW, Wong HT, Ho SK, Johnson PJ. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin Chem 2002; 48: 1021-1027
19. Pouset D, Piller V, Bureaud N, Monsigny M, Piller F. Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. Cancer Res 1997; 57: 4249-4256
20. Halliday JA, Franks AH, Ramsdale TE, Martin R, Palent A. A rapid, semi-automated method for detection of Galbeta1-4GlcNAc alpha2,6-sialyltransferase (EC 2.4.99.1) activity using the lectin Sambucus nigra agglutinin. Glycobiology 2001; 11: 557-564
21. Dall’Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001; 18: 841-850
22. Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest 2002; 82: 1515-1524
23. Dall’Olio F, Chiricolo M, D’Errico A, Grupponi E, Altimiri A, Fiorentino M, Grigioni WF. Expression of betagalactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology 2004; 14: 39-49
24. Svensson EC, Conley PB, Paulson JC. Regulated expression of alpha 2,6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP. J Biol Chem 1992; 267: 3466-3472
25. Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguy A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma 2000; 19: 281-286
26. Kaneko Y, Yamamoto H, Kersey DS, Colley KJ, Leestma JF, Moskal JR. The expression of Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase and alpha 2,6-linked sialo-glycoconjugates in human brain tumors. Acta Neuropathol (Berl) 1996; 91: 284-292

Science Editor Guo SY Language Editor Elsevier HK